System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Roberto Edoardo Villa is an expert in Cardiology at Complexo Hospitalario Universitario A Coruña (Spain). As of October 2026, ScienceLeadR ranks Roberto Edoardo Villa in the top 1% of experts worldwide for Cardiomyopathies and Aortic Valve Disease. Roberto Edoardo Villa has authored 455 publications, the most recent in 2026, and is an investigator in 10 clinical trials, 2 of them ongoing. SLR score: 2,499 (community average: 125). How the SLR is computed.

LeadR Profile

Roberto Edoardo Villa Complexo Hospitalario Universitario A Coruña Spain
2 499 ScienceLeadR Reputation 2499

Unlock

Register Login
Network Map

Cardiology

Subspecialties: Public Health - Preventive Medicine - Nutrition

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2002 - 2026
Source: PubMed

Complexo Hospitalario Universitario A Coruña

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 455

Citations

Citations: 8 824 1st author: 30 Last author: 35 Unique author: 1

Main journals

EFSA J 195
Eur Heart J 35
Rev Esp Cardiol 31
Rev Esp Cardiol (Engl Ed) 25
J Am Coll Cardiol 24

Best Journals

Eur Heart J 21
Circulation 9
N Engl J Med 5

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Long-term impact of aficamten on patient-reported outcome measures in obstructive hypertrophic cardiomyopathy: results from FOREST-HCM.
PMID 42544039 — heart failure, cardiomyopathy, hypertrophic, patient reported outcome measures, forests, cardiomyopathies		Eur J Heart Fail20261
Guidance on default values and uncertainty factors to be used by the EFSA Scientific Committee, Scientific Panels and Units in the absence of actual measured data.
PMID 42948457 — absenteeism, uncertainty, body weight		EFSA J20260
Safety and efficacy of a feed additive consisting of Bacillus paralicheniformis DSM 33806 and Heyndrickxia faecalis DSM 32016 (TechnoCare® 50) for piglets (suckling and weaned), pigs for fattening, sows (in order to have benefit in piglets) and all minor growing and reproductive porcine species (Biochem Zusatzstoffe Handels- und Produktionsges. mbH).
PMID 42903565 — skin, safety, bacillus, irritants, drinking		EFSA J20260
Assessment of the feed additive consisting of l-threonine produced with Escherichia coliCGMCC 7.58 for all animal species for the renewal of its authorisation (Langfang Meihua Bio-Technology Co., Ltd.).
PMID 42903617 — escherichia, skin, safety, amino acids, threonine		EFSA J20260
Safety and efficacy of a feed additive consisting of Heyndrickxia faecalisDSM 32016 (TechnoSpore50®) for calves for fattening/rearing, and other bovines, ovines, caprines, cervids and camelids at the corresponding developmental stage (Biochem Zusatzstoffe Handels- und Produktionsgesellschaft mbH).
PMID 42866272 — skin, safety		EFSA J20260

Clinical Studies 10

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

Phase 3 6
Phase 2 2
N/A 1
Phase 2/Phase 3 1

By status:

Completed 7
Active not recruiting 1
Enrolling by invitation 1
Terminated 1

By type:

Interventional 9
Observational 1

By Monocentric/Multicentric:

monocentric 0
multicentric2to4 0
multicentric5to9 0
multicentricup10 10

Main Topics

Cohort/Consortium Investigators 2

Ongoing Clinical Trials

2 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non Obstructive Hypertrophic Cardiomyopathy (nHCM)
NCT06081894 — safety, multiple chronic conditions, tablets, cardiomyopathy, hypertrophic, cardiomyopathies		Phase 3Active not recruiting2023
Open label Extension Study to Evaluate the Long term Safety and Tolerability of Aficamten in Adults With HCM
NCT04848506 — safety, tablets, cardiomyopathy, hypertrophic, research, therapeutics, forests, cardiomyopathies		Phase 2/Phase 3Enrolling by invitation2021

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS